Company intelligence / Profile preview

Cystotech

Ownership: Private
Employees: ~10
Development stage: Other

Overview

Cystotech is developing an AI-powered software support tool to assist urologists in detecting and categorizing bladder cancer in real time during cystoscopy. The technology aims to improve diagnostic accuracy, reduce recurrence rates by enabling more precise tumor grading and resection depth decisions, and ultimately enhance patient outcomes. As of August 2023, the company had raised pre-seed funding for further development; no commercial or pivotal clinical results have been published yet[1][2][5].

Therapeutic areas: Oncology
Modalities: DeviceSoftware as a Medical Device (SaMD)Artificial intelligence-based diagnostic tool
Industry: Digital Health Medical Devices

Partnerships

No major pharmaceutical or biotech partnerships publicly disclosed as of June 2025.

Beyond the preview

Go deeper on Cystotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cystotech.

Explore the full profile